Top-News
Professionelle Dienstleistungen USA

Soligenix News

Aktie
WKN:  A3D506 ISIN:  US8342235053 US-Symbol:  SNGX
0,4074 $
-0,0126 $
-3,00%
02.05.24 21:58:02
Handeln Depot/Watchlist
Aktienanzahl *
10,52 Mio.
Marktkapitalisierung *
3,95 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 06.04.2024

Soligenix News

06.05.24 - PR Newswire
Soligenix to Present at Upcoming Conferences
Soligenix to Present at Upcoming Conferences PR Newswire
25.04.24 - PR Newswire
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa PR Newswire
18.04.24 - PR Newswire
Soligenix Announces Pricing of $4.75 Million Public Offering
Soligenix Announces Pricing of $4.75 Million Public Offering PR Newswire
15.04.24 - PR Newswire
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-​Exposure Prophylaxis Against Marburg Marburgvirus Infection PR Newswire
11.04.24 - PR Newswire
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-​Exposure Prophylaxis Against Sudan Ebolavirus Infection PR Newswire
03.04.24 - PR Newswire
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-​Controlled Trial for HyBryte™ With the European Medicines Agency PR Newswire
15.03.24 - PR Newswire
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results PR Newswire
08.02.24 - PR Newswire
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board PR Newswire
25.01.24 - PR Newswire
Soligenix to Present at The Microcap Conference
Soligenix to Present at The Microcap Conference PR Newswire
08.01.24 - PR Newswire
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease PR Newswire
04.01.24 - PR Newswire
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-​to-Moderate Psoriasis PR Newswire
02.01.24 - PR Newswire
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses PR Newswire
01.12.23 - PR Newswire
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
"HyBryte™ Use in Early-​Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery PR Newswire
30.11.23 - PR Newswire
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease PR Newswire
17.11.23 - PR Newswire
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting PR Newswire
13.11.23 - PR Newswire
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results PR Newswire
20.10.23 - PR Newswire
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting PR Newswire
16.10.23 - PR Newswire
Soligenix to Present at The ThinkEquity Conference
Soligenix to Present at The ThinkEquity Conference PR Newswire
25.09.23 - PR Newswire
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures PR Newswire
22.09.23 - PR Newswire
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders PR Newswire

Newssuche

Videos

newspaper
06.05.24 +6,89%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »